Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy Isabella Ciccone, MPH

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Latest News

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

News All Time

Targeting Myasthenia Gravis at the Source: Promising Progress of CAR-T Agent KYV-101 Marco Meglio

Naji Gehchan, MD, MSc, chief medical and development officer Kyverna, discussed how KYV-101 may redefine generalized myasthenia gravis care through deep B-cell depletion and durable, drug-free remission.

NeuroVoices: Tanya Simuni, MD, FAAN, on Emerging Directions in Disease-Modifying Therapy Trials for Parkinson Disease Tanya Simuni, MD, FAAN, Isabella Ciccone, MPH

At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.

Study shows over 90% of older adults with dementia undergo burdensome interventions in their final year

A new study by researchers from Duke-NUS Medical School has revealed that almost all community-dwelling older adults with advanced dementia in Singapore experience at least one potentially burdensome intervention in their ...

Parents of neurodivergent kids need support. But those who need it most often wait longer

Parenting any young child is full of highs and lows. In addition to these, parents and caregivers of children with neurodevelopmental conditions such as autism and attention-deficit hyperactivity disorder (ADHD) are more ...

What polymers can teach us about curing Alzheimer's disease

Researchers from Tokyo Metropolitan University have applied ideas from polymer physics to illuminate the mechanism behind a key pathology in Alzheimer's disease, the formation of fibrils of tau proteins. They showed that ...

Mild cognitive impairment, dementia risk up with increasing biological severity of Alzheimer's disease

For individuals who are currently cognitively unimpaired, the lifetime and 10-year absolute risk of mild cognitive impairment (MCI) and dementia increases with increasing amyloid positron emission tomography (PET) centiloid ...

Gene 'switch' reverses Alzheimer's risk in experimental model

University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer's disease treatments by targeting one of the brain's most important genes for risk and resilience.

Next-generation microbiome medicine may transform Parkinson's treatment

The age-old advice to "trust your gut" could soon take on new meaning for people diagnosed with Parkinson's disease, thanks to a creative feat of bioengineering by researchers in the University of Georgia's College of Veterinary ...

How people identify scents and perceive their pleasantness

In a new JNeurosci paper, Masako Okamoto and colleagues, from the University of Tokyo, explored the brain activity involved in smelling odors.

Brain stimulation found to improve vision recovery after stroke

Scientists at EPFL have developed an innovative, non-invasive brain stimulation therapy to significantly improve visual function in stroke patients who have suffered vision loss following a stroke. The approach could offer ...

Poor sleep may nudge the brain toward dementia, researchers find

Staring at the ceiling while the clock blinks 3am doesn't only sap energy for the next day. A large, long-running U.S. study of older adults has now linked chronic insomnia to changes inside the brain that set the stage for ...

How to keep dementia from robbing your loved ones of their sense of personhood—tips for caregivers

Every three seconds, someone in the world develops dementia. There are over 6 million people living with dementia in the U.S. and 57 million globally.

Exercise-induced vesicles boost neuron growth when transplanted into sedentary mice

Researchers at the University of Illinois Urbana-Champaign report that extracellular vesicles released into the bloodstream during aerobic exercise can, on their own, drive a robust increase in adult hippocampal neurogenesis ...

Unusual days signal rising migraine risk

Harvard Medical School researchers report that higher day-to-day "trigger surprisal" scores were associated with migraine attacks over the next 12 and 24 hours. In this cohort, higher surprisal scores aligned with greater ...

Neural 'barcodes': Intra-regional brain dynamics linked to person-specific characteristics

People can think, behave and function very differently. These observed differences are known to be the result of complex interactions between genetics, neurobiological processes and life experiences.

How brain fluid flow predicts survival in glioblastoma

Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most patients survive only about a year after diagnosis.

Recommended News For You

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

Chemo causes lasting physical decline in breast cancer survivors

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

AI-based breast cancer risk technology receives FDA breakthrough device designation

New CAR T-Cell Therapy Approved for Leukemia

Housing aid linked to lower medical financial hardship among US renters with cancer

Recommended Articles For You

Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor 

The Mystery of Carotid Body Tumors: The Facts You Need to Know 

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research 

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

2.

Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

3.

For elderly, unfit patients, the all-oral AML regimen shows promise.

4.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

5.

New analysis helps discern benign from malignant thyroid growths

1.

The Role of Alanine Aminotransferase in Liver Health and Disease 

2.

Myeloproliferative Disorders: Causes, Symptoms and Treatment Options 

3.

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?

4.

The Importance of Corrected Calcium Levels in Managing Health Conditions 

5.

Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

4.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot